Glomerulonephritis Latest Advances

Prevalence of anti-rituximab antibodies in autoimmune forms of glomerulonephritis and podocytopathies.

Journal: Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association

Published: June 24, 2026

Serum RIPK3/MLKL as exploratory biomarker candidates for systemic lupus erythematosus.

Journal: Lupus

Published: June 24, 2026

Atrasentan: new molecule in the therapy of IgA nephropathy and other glomerulopathies.

Journal: Ceska a Slovenska farmacie : casopis Ceske farmaceuticke spolecnosti a Slovenske farmaceuticke spolecnosti

Published: June 23, 2026

Addressing challenges in disease management of childhood-onset systemic lupus erythematosus: the role of biologics, with a primary focus on rituximab and belimumab.

Journal: Expert opinion on biological therapy

Published: June 23, 2026

Clinical significance of serum complement levels and C3/C4 ratio in IgA nephropathy: histopathological correlates and prognostic implications.

Journal: Renal failure

Published: June 23, 2026

Clinical and histopathological predictors of systemic lupus erythematosus in a South American cohort of patients with full-house glomerulonephritis.

Journal: Lupus

Published: June 23, 2026

The successful use of rituximab in children with IgA nephropathy and minimal change-like lesions: a case series.

Journal: Renal failure

Published: June 23, 2026

Bortezomib-Cyclophosphamide-Dexamethasone versus Rituximab in PGNMID -Dexamethasone versus Rituximab in PGNMID.

Journal: Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association

Published: June 23, 2026

Albuminuria Changes as a surrogate endpoint in Apolipoprotein L1 Mediated Kidney Disease in Vanderbilt BioVU and the Million Veteran Program.

Journal: medRxiv : the preprint server for health sciences

Published: June 22, 2026

Erratum Regarding "The Association of Class I and II Human Leukocyte Antigen Serotypes With End-Stage Kidney Disease Due to Membranoproliferative Glomerulonephritis and Dense Deposit Disease" (Am J Kidney Dis. 2024;83(1):79-89).

Journal: American journal of kidney diseases : the official journal of the National Kidney Foundation

Published: June 19, 2026

Evaluation of Puromycin-Induced Podocyte Injury and Protective Effects of Voclosporin Using Induced Pluripotent Stem Cells from a Patient with Nephrotic Syndrome Harboring an INF2 Variant.

Journal: Stem cells and development

Published: June 18, 2026

When Atypical Becomes Typical: A Fulminant Seronegative Anti-GBM Disease.

Journal: Kidney medicine

Published: June 17, 2026

Glomerulonephritis Latest Advances

Find the Latest Research About Glomerulonephritis

Prevalence of anti-rituximab antibodies in autoimmune forms of glomerulonephritis and podocytopathies.

Prevalence of anti-rituximab antibodies in autoimmune forms of glomerulonephritis and podocytopathies.

Serum RIPK3/MLKL as exploratory biomarker candidates for systemic lupus erythematosus.

Serum RIPK3/MLKL as exploratory biomarker candidates for systemic lupus erythematosus.

Atrasentan: new molecule in the therapy of IgA nephropathy and other glomerulopathies.

Atrasentan: new molecule in the therapy of IgA nephropathy and other glomerulopathies.

Addressing challenges in disease management of childhood-onset systemic lupus erythematosus: the role of biologics, with a primary focus on rituximab and belimumab.

Addressing challenges in disease management of childhood-onset systemic lupus erythematosus: the role of biologics, with a primary focus on rituximab and belimumab.

Clinical significance of serum complement levels and C3/C4 ratio in IgA nephropathy: histopathological correlates and prognostic implications.

Clinical significance of serum complement levels and C3/C4 ratio in IgA nephropathy: histopathological correlates and prognostic implications.

Clinical and histopathological predictors of systemic lupus erythematosus in a South American cohort of patients with full-house glomerulonephritis.

Clinical and histopathological predictors of systemic lupus erythematosus in a South American cohort of patients with full-house glomerulonephritis.

The successful use of rituximab in children with IgA nephropathy and minimal change-like lesions: a case series.

The successful use of rituximab in children with IgA nephropathy and minimal change-like lesions: a case series.

Bortezomib-Cyclophosphamide-Dexamethasone versus Rituximab in PGNMID -Dexamethasone versus Rituximab in PGNMID.

Bortezomib-Cyclophosphamide-Dexamethasone versus Rituximab in PGNMID -Dexamethasone versus Rituximab in PGNMID.

Albuminuria Changes as a surrogate endpoint in Apolipoprotein L1 Mediated Kidney Disease in Vanderbilt BioVU and the Million Veteran Program.

Albuminuria Changes as a surrogate endpoint in Apolipoprotein L1 Mediated Kidney Disease in Vanderbilt BioVU and the Million Veteran Program.

Erratum Regarding "The Association of Class I and II Human Leukocyte Antigen Serotypes With End-Stage Kidney Disease Due to Membranoproliferative Glomerulonephritis and Dense Deposit Disease" (Am J Kidney Dis. 2024;83(1):79-89).

Erratum Regarding "The Association of Class I and II Human Leukocyte Antigen Serotypes With End-Stage Kidney Disease Due to Membranoproliferative Glomerulonephritis and Dense Deposit Disease" (Am J Kidney Dis. 2024;83(1):79-89).

Evaluation of Puromycin-Induced Podocyte Injury and Protective Effects of Voclosporin Using Induced Pluripotent Stem Cells from a Patient with Nephrotic Syndrome Harboring an INF2 Variant.

Evaluation of Puromycin-Induced Podocyte Injury and Protective Effects of Voclosporin Using Induced Pluripotent Stem Cells from a Patient with Nephrotic Syndrome Harboring an INF2 Variant.

When Atypical Becomes Typical: A Fulminant Seronegative Anti-GBM Disease.

When Atypical Becomes Typical: A Fulminant Seronegative Anti-GBM Disease.